We detected the expression level of PRDM1 in CD4+ T cells and CD8+ T cells from bone marrow (BM) allografts or peripheral blood (PB) allografts and monitored for the occurrence of GVHD after HSCT for 2 years. Here, PRDM1 is linked to graft versus host disease.